How many drugs treat Bacterial endocarditis?

Drug Landscape tracks 10 marketed treatments for Bacterial endocarditis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/bacterial-endocarditis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bacterial endocarditis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bacterial endocarditis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bacterial endocarditis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Primaxin	CILASTATIN	Merck & Co.	Renal Dehydropeptidase Inhibitor	Dipeptidase 1	1985-01-01
Primaxin	IMIPENEM	Merck Sharp & Dohme B.V.	imipenem		1985-01-01
Cefaprin	cefapirin	Bristol-Myers Squibb	cefapirin	Sigma non-opioid intracellular receptor 1	1974-01-01
Ancef In Sodium Chloride 0.9% In Plastic Container	CEFAZOLIN	GSK	Cephalosporin Antibacterial		1973-01-01
Ancef In Sodium Chloride 0.9% In Plastic Container	Cefazolin Sodium	GSK	Cephalosporin	Bacterial cell wall peptidoglycan	1973-01-01
Unasyn	AMPICILLIN	Bristol-Myers Squibb	Penicillin-class Antibacterial	Transient receptor potential cation channel subfamily M member 4	1965-01-01
Metro I.V. In Plastic Container	METRONIDAZOLE	Baxter	Nitroimidazole Antimicrobial [EPC]		1963-01-01
Penicillin G Potassium In Plastic Container	Benzylpenicillin	Pfizer	Penicillin-class Antibacterial		1947-01-01
Vancocin	vancomycin	ANI Pharmaceuticals		Alpha-2A adrenergic receptor, D-alanyl-D-alanine dipeptidase, UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase
Cefazoline	Cefazoline	Nantes University Hospital		Bacterial penicillin-binding protein, Penicillin-binding protein 1A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

GSK · 2 drugs in Bacterial endocarditis
Bristol-Myers Squibb · 2 drugs in Bacterial endocarditis
HaEmek Medical Center, Israel · 1 drug in Bacterial endocarditis
Karlstad University · 1 drug in Bacterial endocarditis
Merck & Co. · 1 drug in Bacterial endocarditis
Merck Sharp & Dohme B.V. · 1 drug in Bacterial endocarditis
Nantes University Hospital · 1 drug in Bacterial endocarditis
Pfizer · 1 drug in Bacterial endocarditis
ANI Pharmaceuticals · 1 drug in Bacterial endocarditis
University of Oslo · 1 drug in Bacterial endocarditis
Baxter · 1 drug in Bacterial endocarditis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bacterial endocarditis:

Cite this brief

Drug Landscape (2026). Bacterial endocarditis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bacterial-endocarditis. Accessed 2026-06-10.

Bacterial endocarditis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing